The Italian Competition Authority closes a monitoring procedure into Aspen compliance with a previous infringement decision
By the decision made on 13 June 2018 in the Case A408B Aspen- Prezzi farmaci antitumorali , the Italian Competition Authority (ICA) closed a monitoring pursuant to Article 15 of the Italian Competition Law no 287/1990 against the producer of generic drugs Aspen. By its previous decision of 29 September 2016 , the ICA had found Aspen liable to have breached Article 102 TFEU by applying excessive prices for the Cosmos drugs used for the treatment of cancer during the 2013-2014 period. The ICA infringement decision was then upheld on appeal by the Regional AdministrativeCourt of Latium , whose judgment is current under appeal before the Council of State. Following the infringement decision, in February 2017 the Italian Drug Authority (AIFA) started the procedure for the revision of the prices for the Cosmos drugs in accordance with the findings of the ICA. The prices proposed by Aspen to the AIFA only partially complied with the criteria laid down by the ICA. Moreover, the documents